Parkinson’s disease (PD) is a type of disease in the nervous system that is second only to Alzheimer’s disease, and sometimes it is difficult to distinguish it from other neurodegenerative diseases in diagnosis. The development and research of biomarkers are helpful to promote the early diagnosis and disease monitoring of PD. Creative BioMart Biomarker is one of the experts who are professional in single biomarker detection. We have years of biomarker detection experience and advanced technology platform to provide fast, sensitive and repeatable PD biomarker detection services according to customer needs.
PD is a type of neurological disease caused by the lack of dopamine. Dopamine is a neurotransmitter related to exercise, memory and other functions. The clinical characteristics of PD patients are mainly bradykinesia, muscle stiffness, postural instability and resting tremor. In addition, it may also present non-motor symptoms such as olfactory dysfunction, autonomic nerve abnormalities, sleep problems and constipation. The main pathological features of PD are the gradual degeneration of dopaminergic neurons in the substantia nigra and the accumulation of intra-neural inclusions of α-synuclein. The symptoms and signs of PD usually develop after 70-80% of dopamine neurons degenerate. The disease progression stages of PD include preclinical PD stage, prodromal PD stage and clinical PD stage. Among them, the neurodegenerative process occurs in the preclinical PD stage but is not accompanied by obvious symptoms or signs. The symptoms or signs appear in the prodromal PD stage, but it is not enough to confirm the disease. Until the clinical PD stage, the diagnosis of the disease can be based on the patient’s symptoms or signs. Therefore, the clinical diagnosis of PD is mainly based on the clinical characteristics of patients, but PD and many neurodegenerative diseases have common clinical features, such as corticobasal degeneration, multiple system atrophy, and dementia with Lewy bodies, which will increase the complexity of PD diagnosis and increase the misdiagnosis rate of early PD. The introduction of biomarkers can objectively evaluate disease or physiological changes, which is conducive to early diagnosis of PD and monitoring of disease progression. Some candidate biomarkers related to PD have been found in blood, cerebrospinal fluid, and saliva samples, such as 8-Hydroxydeoxyguanosine and α-synuclein. However, in order to screen out more sensitive and specific biomarkers and improve the accuracy of PD diagnosis, more research on PD-related biomarkers is needed.
Figure 1. The dopaminergic system in the brain (Man, et al. 2018)
Creative BioMart Biomarker offers a wide range of PD related biomarker detection based on customer needs. Through advanced instruments, we accept different samples of different concentrations and ensure a wide kinetic range to detect samples of different concentrations. In addition, different biomarkers have different detection effects in different samples, we can customize the detection plan according to customer needs, and obtain the ideal test results with appropriate samples and advanced detection methods.
Creative BioMart Biomarker strictly controls each specific experimental step in the detection procedure to ensure accurately quantify the level of biomarkers related to PD in each sample.
At Creative BioMart Biomarker, we not only provide high-quality PD biomarker detection service, but also provide detection services for other biomarkers. Additionally, our experts can also provide and help design a proper technological scheme according to your specific requirements. Please feel free to contact us, Creative BioMart Biomarker is here to offer you professional and thoughtful service.